title: [A case of erythroleukemia associated with lung aspergilloma successfully treated with continuous drip infusion of amphotericin B].
abstract: In September 1990, a 55-year-old female with erythroleukemia was treated with enocitabine, mitoxantrone, vincristine, and etoposide. Despite prophylaxis of infectious diseases by oral administration of 2,400 mg/day amphotericin B (AMPH), 600 mg/day ofloxacin, and 1,500 mg/day kanamycin, pneumonia with refractory pyrexia appeared and developed cystic lesions with air crescent signs thereafter. Finally, the cystic one formed fungus balls. The pneumonia was diagnosed as aspergillus pneumonia by fungus growth in the tissue in the transbronchial lung biopsy specimens and by an elevation of serum anti-Aspergillus antibody. The patient had continuously been administered with AMPH for 16 days, increasing the drug doses every 2 days. The maximum plasma level of AMPH rose up to 0.78 micrograms/ml, the total amount up to 166 mg. The fungus balls disappeared completely without adverse effects except a transient decrease of plasma potassium level. Pharmacological studies had been reported that tissue AMPH levels elevated more than twice as much as that of the plasma. Although the maximum plasma level was less than that of MIC for Aspergillus, the lung tissue drug level was suspected to have been maintained higher by continuous drip infusion. These findings indicate that continuous drip infusion of AMPH is one of the useful treatment for lung aspergillosis.
authors.affiliation: First Department of Internal Medicine, Fukui Medical School.
authors.forename: K
authors.initials: K
authors.lastname: Inai
authors.forename: T
authors.initials: T
authors.lastname: Ueda
authors.forename: D
authors.initials: D
authors.lastname: Kagawa
authors.forename: H
authors.initials: H
authors.lastname: Iwasaki
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007262:Infusions, Intravenous; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged
chemical_list: D000666:Amphotericin B